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Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has recently emerged 
in the world. There are limited data describing the clinical progression of COVID-19 in transplanted patients. In 
the general population, clinical presentation ranges from asymptomatic infection to severe pneumonia and may 
also develop renal failure. In kidney transplant (KT) patients, management of these patients was mainly based on 
anecdotal experience. 
CASE REPORT: We report our first experience of KT patients with COVID-19. A 49-year-old male with KT in 2017 
presented on March 20, 2020, with fever, weakness, smell loss, chest pain, and caught. On chest X-ray, he presented 
ground-glass opacities and bilateral pneumonia. There was a slight progression to acute hypoxic respiratory failure. 
We reduced immunosuppression therapy and since we suspected seasonal flu, we applied available antiviral 
oseltamivir till confirmation of RNA sequence of the SARS-CoV-2 virus. Moreover, we applied azithromycin and 
broad spectrum of antibiotics as well as an anticoagulant therapy. Graft function remained stable during 14 days 
of hospitalization. The patient clinically improved with decreasing oxygen requirements and manifested clinical 
recovery. After two negative PCR test, he was discharged and immunosuppression therapy was returned to previous. 
CONCLUSION: This case highlights the importance of earlier outpatient hospitalization and testing which may 
improve COVID-19 outcomes among transplanted patients.
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Introduction
In December 2019, in Wuhan, China, a new 
disease appeared that caused severe pneumonia and 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV2) was detected as a causative agent. Disease 
was called coronavirus disease 2019 (COVID-19). It 
was spread very fast to all continents, and on March 11, 
2020, the World Health Organization (WHO) declared a 
pandemic [1]. It has been shown that virus was transmitted 
from person to person during unprotected contact, 
respiratory droplet, fecal-oral transmission, and vertical 
transmission from mother to child [2]. Moreover, it was 
shown that it uses ACE 2 receptors to enter the cell, similar 
to SARS-CoV. The clinical presentation is very diverse, 
from asymptomatic, mild, and moderate to severe [3].
Patients with transplanted kidneys are on 
continuous immunosuppressive therapy. Previous 
experiences with SARS and MERS have described 
deteriorating graft function in infections, even with a fatal 
outcome [4], [5]. At the root of dealing with them, as well 
as in all infections, is actually timely modifications or 
discontinuation of immunosuppressive therapy, except 
for corticosteroids according to the recommendations and 
appropriate specific therapy [6], [7]. It has been reported 
that in KT patients with COVID-19, it is necessary to 
modify the immunosuppressive therapy; unfortunately, 
there is a lack of reports about appropriate specific 
therapy for SARS-CoV-2 in KT patients [8], [9], [10].
First imported case of COVID-19 was detected in 
our country on February 21, 2020, and until May 15, 2020, 
there were a total number of 1723 patients, 1235 cured, 
including 1 KT patient and 7 patients on dialysis [11].
Case Report
We present here our first experience with 
COVID-19 in a 49-year-old male kidney transplant 
patient. He was transplanted 3 years ago, and the donor 
was his brother. Treated according to a protocol with four 
immunosuppressive therapies, Basiliximab as induction 
therapy and triple immunosuppressive maintenance 
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therapy that included corticosteroids, cyclosporine 
A (Cy A), and mycophenolic acid (MMF). From 
comorbidities present arterial hypertension, regulated 
by the following antihypertensive oral therapy: Calcium 
antagonist (nifedipine R a 20 mg 3 × 1), angiotensin 
II receptor blocker (ARB) losartan a 50 mg 2 × 1 and 
carvedilol a 6.25 mg 2 × 1, and obesity with body mass 
index (BMI) = 37.7. The patient regularly came for regular 
follow-up. No signs of transplant rejection were recorded 
during follow-up. Kidney function was stable, with values 
for serum creatinine of 110 µmol/L and calculated GFR 
of 109 ml/min, on the last control on March 3, 2020. The 
patient was given to sign a written consent.
On March 20, 2020, the patient experienced 
the first symptoms such as weakness, pain in the knees 
and hips, temperature up to 38.5°C, loss of taste and 
smell, and chest pain. According to the protocols of our 
Ministry of Health, the patient called the epidemiological 
services. Because the patient had a negative 
epidemiological history, he was referred to his general 
doctor with suspicion of seasonal flu. Oral treatment 
with ciprofloxacin a 500 mg 2 ° 1 and oseltamivir a 
75 mg 2 × 1 (Tamiflu) was started immediately. The 
dose of cyclosporine A (Cy A) and MMF was reduced 
by 50% of baseline.
The temperature persisted and a persistent 
dry cough appeared, indicating that the patient needs 
to be tested. On March 23, 2020, a diagnosis of 
COVID 19 was made by proving the presence of an 
RNA sequence of the SARS-CoV-2 virus in the material 
from the nasal and throat swab. The same day, the 
patient was hospitalized at the University Clinic for 
Infectious diseases and febrile conditions.
At the time of admission, the patient was 
febrile 38°C and the physical status was positive. The 
auscultatory chest findings were in favor of sharper 
vesicular breathing.
The initial laboratory test showed an orderly 
leukocyte count, but a reduced lymphocyte count 
slightly elevated C reactive protein (CRP) and creatinine 
kinase (CK). The graft function was normal, but values 
for serum potassium were close to the lower limit. The 
hemostasis finding indicated lower platelet counts and 
a slight increase in d-dimers (Tables 1 and 2). The chest 
X-ray showed bilateral pneumonia (Figure 1).
The immunosuppressive therapy Cy A and 
MMF were discontinued and oral decortin a 15 mg 
were given as maintenance therapy. The ARB was 
interrupted. The rest of the therapy consisted of 
intravenous ceftriaxone a 2g 2 × 1, azithromycin a 
500 mg 1 × 1, paracetamol when needed, subcutaneous 
clexane, and other oral supportive therapy such as 
Vitamin C, probiotics, potassium supplements, and 
hepatoprotectants (Table 3).
The patient after 9 days was afebrile. Of all the 
other symptoms, the dry cough lasted longer (Table 4). 
Regarding the laboratory findings, there has been a 
continuous improvement in the number of lymphocytes, 
platelets, as well as serum values for CRP and CC. A 
moderate increase in d-dimers and moderate transaminase 
activity also has been observed (Tables 1 and 2). The graft 
function remained stable with serum creatinine 97 µmoll/L.
Table 1: Biochemical findings during hospitalization
??? March 24 March 28 April 02 April 04
Hb g/L 141 140 136 138
RBC 10ˆ12/L 4.6 4.7 4.6 4.6
WBC 10ˆ9/L 4.4 7.5 7.4 5.8
PLT 10ˆ9/L 123 166 264 259
Htc rv 0.40 0.39 0.38 0.40
Ne 10ˆ9/L 0.84 0.87 0.67 0.63
Ly 10ˆ9/L 0.08 0.07 0.16 0.20
Mo % 0.08 0.06 0.15 0.15
Eo % 0,02 0,02
Glucose mmoll/L 5.3 6.9 5.0 5.2
Urea mmoll/L 7,0 4,0 3,9 4,4
Creatinine/µmoll/L 100 102 104 97
Tot.bil µmoll/L 11
Dir/ind µmoll/L 3/8
ALT U/L 41 88 80
AST U/L 36 54 38
LDH U/L 161 334 316 244
CK U/L 239 231 93
CK-MB U/L 14 17
GGT U/L 23
Troponin ng/ml 34.6
K mmoll/L 3.6 3.0 2.9 3.3
Na mmoll/L 138 133 138 138
Ca mmoll/L 2.2 2.2 2.16 2.2
Total proteins g/L 65
Globulins g/L 29
Albumins g/L 36
CRP mg/L 45 87 30 6
Hb: Hemoglobin, RBC: Red blood cell, WBC: White blood cell, PLT: Platelet, Ne: Neutrophils,  
Ly: Lymphocytes, Mo: Monocytes, Eo: Eosinophils, Tot.bil: Total bilirubin, dir/ind: Direct/indirect, ALT: 
Alanine Transaminase, AST: Aspartate aminotransferase, LDH: Lactate dehydrogenase, CK: Creatine 
kinase, CK-MB creatine kinase: MB, GGT: Gamma-glutamyl transferase, K: Kalium, Na: Sodium, Ca: 
Calcium, CRP: C Reactive protein
Figure 1: Bilateral pneumonia (chest X-ray on the 3th day)
After 15 days of hospitalization and two 
consecutive negative nasal and throat swab tests 
for SARS-CoV-2, the patient was discharged. After 
discharge, the Cy A and MMT therapy were restarted, 
gradually within 7 days to previous maintenance dosage. 
On the first control 12 days after hospitalization, renal 
function was unchanged and chest X-ray picture finding 
showed resolving of pneumonia (Figure 2).
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Discussion
From the current findings, the biggest risk of 
becoming infected with COVID-19 disease is through 
contact with a person with respiratory disease, 
but the fact that we have a patient with a negative 
epidemiological survey indicates that the spread of 
infection by asymptomatic carriers is also important [12]. 
In terms of gender and age, it has been reported that 
men and advanced age play a role in the severity of 
clinical presentation and mortality [13].
Patients with a КТ are undergoing permanent 
immunosuppressive therapy, which causes a state of 
immunocompromised and often consequently, the 
infective diseases can have a changed clinical picture. 
In our first case, the clinical manifestations were fever, 
high temperature, dry cough, malaise, joint pain, and 
loss of sense of smell and taste, symptoms identical to 
those of the general population[2].
Clinical presentation may vary from 
asymptomatic to severe needing respiratory support. 
The presence of other comorbidities and conditions, 
such as high blood pressure, diabetes mellitus, 
chronic heart disease, chronic respiratory disease, 
and obesity, has been described as risk factors 
not only for the onset of COVID-19 but also for the 
progression and severity of clinical presentation. In 
our case, the patient was also overweight and had 
high blood pressure, which was probably the reason 
for the presentation of moderate to severe clinical 
picture, but without the need for oxygen support or 
respirator [14], [15].
Long-term use of immunosuppressive therapy 
is a reason to reduce T lymphocytes and reduce 
immunity in patients with transplanted organs. Therefore, 
modification or total cessation of immunosuppressive 
therapy, especially of MMF and Cy A, is extremely 
important in all infections but also in COVID-19 [6], [9]. 
In our case, the patient was on triple maintenance 
therapy: Corticosteroids, MMF, and Cy A. During the 
first three days, the dose of MMF and Cy A was reduced 
by 50%, and on the day of hospitalization they were 
discontinued. Table decortin 15 mg/day was established 
as maintenance therapy. Although experience has 
suggested that the МMF and calcineurin inhibitor should 
be discontinued, there are some studies that suggest 
that Cy A inhibits the replication of the SASR-CoV 
virus in cell culture [16], [17]. The patient also received 
ARBs therapy and was discontinued despite insufficient 
Table 2: Hemostasis findings during hospitalization
Date PLT
10ˆ9/L
Hematocrit Prothrombin time (s)
(9.8–14.2)
Activated partial (s)
(27.9–29.1)
Thrombin time (s)
(16.1–19.01)
d-dimers
(0–500)
March, 24 111 41.3 10.2 29.1 17.2 581
April, 05 253 39.9 10.36 25.5 19.01 1004
Figure 2: Findings resolved (chest X-ray after 24 days)
Table 3: Duration of clinical signs and symptoms
-3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Temperature 38.0 38.4 38.3 37.4 38.5 36.4 38.3 38.6 38.5 37.3 37.2 37.5 37.5 37.5 37.1 37.1 36.6 36.8 36.6
Fever
Dry cough
Chest pain
Pain in the knees and hips
Loss of taste and smell
SpO2 % 92 90 91 86 92 91 95 96 95 97 97 95
Table 4: Therapeutic approach before and during the hospitalization
Therapy/days -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Decortin mg 5 5 5 5 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15
MMF 1 g/day
Cy A  50 WWmg/day
Caps. Oseltamivir a 75 mg 2 × 1
Tab. Ciprofloxacin a 500 mg 2 × 1
Amp. Ceftriaxon a 2 g/day
Amp. Azitromycin a 500 mg/day
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evidence that ACE inhibitors and ARBs may cause a 
more severe clinical picture [18], [19], [20].
So far, it has been reported that there have 
been a number of disturbances in the biochemical 
analyses of patients with COVID-19. Lymphocytopenia 
is the most common finding. Necrosis or apoptosis 
of the lymphocytes is a possible mechanism. In non-
critical patients infected with SARS CoV-2, up to 37% 
had mild lymphocytopenia and up to 80% in critically 
ill patients. In our case, there was no change in the 
total number of leukocytes, but there was initially a 
decrease in the number of lymphocytes to 0.07, with a 
gradual increase to 0.20. An increase in CRP to 87 was 
registered, followed by its normalization [21], [22].
It is known that SARS-CoV-2 binds to ACE 2 
receptors and can enter the cells of the renal tubules 
and cause acute renal failure [15], [23], [24]. In our 
patient, graft function remained steady, with serum 
creatinine values ranged from 104 to 97 µmoll/L. Mild 
hypokalemia was noted in the absence of diarrhea and 
forced diuresis with potassium-sparing diuretics, which 
may be explained by the above.
SARS-CoV-2 can penetrate and replicate in 
hepatocytes. In 15% of patients who do not have a need 
for intensive care treatment, an increase in AST and 
ALT is observed. The same goes for the hepatic lesion 
in our case, with a gradual spontaneous recovery [25].
The presence of coagulopathy in COVID-19 is 
usually explained by a secondary bacterial infection and 
an increase in CRP. It is manifested by a decrease in 
platelet count and an increase in d-dimers, in our case 
111 and 2500, respectively, and in some severe cases 
with the development of disseminated intravascular 
coagulopathy [26].
Pneumonia was confirmed by the finding of 
chest X-ray, as in other cases with COVID-19. Since there 
was no worsening in the condition, there has not been 
an indication for computer tomography (CT) of the lungs 
which is otherwise a method with a very high sensitivity 
of 98% for diagnosing COVID-19. Despite the extensive 
findings and the prolonged dry cough, the patient was 
without oxygen support at all times [27], [28], [29].
The use of a certain group of antibiotics such 
as the azithromycin has been shown to be effective in 
treatment. Certain centers have reported the benefits of 
combining it with chloroquine, but there have been those 
who have not responded. For severe cases, there are 
attempts to treat them with antiviral therapy like remdesivir. 
Special success has been achieved in certain cases 
with plasma delivery from a convalescent patient rich in 
antibodies. For cases combined with severe anemia in 
addition to blood substitution, successful extracorporeal 
membrane oxygenation (ECMO) treatments have been 
reported. Furthermore, tocilizumab is reported as an 
effective treatment in severe patients of COVID-19. 
However, there is still no specific therapy or vaccine for 
COVID-19 [30], [31], [32], [33], [34].
Conclusion
Our first experience showed that the clinical 
presentation of COVID-19 in a kidney transplanted 
recipient is the same as in the general population. 
Treatment with azithromycin and cephalosporin 
antibiotics has been shown to be effective in the 
treatment of bilateral pneumonia, along with the 
modification of immunosuppressive therapy. Since there 
is still no specific therapy, the latter seems to be of great 
importance not only for improving immunity but also for 
a positive clinical outcome. Experience and analysis of 
several cases are required to reach a conclusion about 
the treatment and outcome in kidney transplant recipient 
and COVID 19, which is the limitation in this presentation.
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